---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092654"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:53:24.311529+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tenaya enters cardiovascular gene target collaboration with Alnylam; up to $10M upfront, $1.13B milestones

## Summary
- Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.
- Tenaya receives up to $10M upfront payment within 30 days, subject to reductions for targets not advanced.
- Tenaya eligible for up to $1.13B in development, regulatory, and sales milestones for company-nominated targets.
- Alnylam gets exclusive worldwide license; may unilaterally terminate for any reason. Tenaya restricted on certain targets.
- Alnylam reimburses Tenaya for FTEs and out-of-pocket costs per research budget; each party covers own costs otherwise.

## SEC filing metadata
- accession: 0001193125-26-092654
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312526092654/0001193125-26-092654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312526092654/tnya-20260304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092654
- JSON: https://secwatch.observer/filing/0001193125-26-092654.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092654.txt

## Key facts
- Material Agreements
  Tenaya Therapeutics, Inc. entered into Collaboration Agreement with Alnylam Pharmaceuticals, Inc. valued at up to $10.0 million (effective 2026-03-04).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Alnylam Pharmaceuticals, Inc.
  - Value: up to $10.0 million
  - Effective: 2026-03-04
  source text: On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000119312526092654/0001193125-26-092654-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.